The analyses demonstrated that mutation in FAT1 could be used as a predictive indicator for efficacy of ICBs, while mutation in KEAP1 acted as a prognostic but not predictive biomarker in NSCLC patients receiving treatment with ICB. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.